A key consideration in using VEGFR TKIs in ACC is that all VEGFR TKIs are metabolized by CYP3A4 and mitotane is a strong CYP3A4 inducer, leading to significant drug interactions with all VEGRF TKIs except lenvatinib. The gene discussed is KDR; the disease is adrenal cortex carcinoma.